Combining multiple agents and fine-tuning selective inhibitors which spare IR while impairing the pro-cancer functional significance of IGF-1 might be accomplished by further examining the structural differences and binding peculiarities of IGF-1R and IR. The gene discussed is IGF1R; the disease is cancer.